ADCYAP1R1 and migraine disorder: A phase 2a, randomized, double blind, placebo-controlled study is underway to appraise the efficacy and safety of a PAC1 receptor antibody (AMG 301) in subjects with chronic or episodic migraine (Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention.https://clinicaltrials.gov/ct2/show/NCT03238781.